Sarep­ta shares PhII da­ta for next-gen ex­on skip­ping drug, but reg­u­la­to­ry path­way is un­clear

Sarep­ta Ther­a­peu­tics an­nounced Mon­day that its ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy drug led to some ex­pres­sion of dy­s­trophin — the mus­cle pro­tein that is mu­tat­ed in peo­ple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER